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Abstract
Background: Polymorphisms in dopaminergic genes may influence cigarette smoking by their potential
impact on dopamine reward pathway function. A1 allele of DRD2 gene is associated with a reduced
dopamine D2 receptor density, and it has been hypothesised that A1 carriers are more vulnerable to
smoking. In turn, the 9-repeat allele of dopamine transporter gene (SLC6A3) has been associated with a
substantial reduction in dopamine transporter, what might result in the higher level of dopamine in the
synaptic cleft, and thereby protective role of this allele from smoking. In the present study we investigated
whether polymorphic variants of DRD2 and SLC6A3 genes and their combinations are associated with the
smoking habit in the Polish population.
Methods:  Genotyping for TaqIA  polymorphism of DRD2  and  SLC6A3  VNTR polymorphism was
performed in 150 ever-smokers and 158 never-smokers. The association between the smoking status and
smoking phenotypes (related to the number of cigarettes smoked daily and age of starting regular
smoking), and genotype/genotype combinations was expressed by ORs together with 95% CI. Alpha level
of 0.05, with Bonferroni correction whenever appropriate, was used for statistical significance.
Results: At the used alpha levels no association between DRD2 and SLC6A3 genotypes and smoking status
was found. However, A1 allele carriers reported longer abstinence periods on quitting attempts than non-
carriers (p = 0.049). The ORs for heavier smoking were 0.38 (0.17-0.88), p = 0.023, and 0.39 (0.17-0.88),
p = 0.021 in carriers compared to non-carriers of A1 or *9 allele, respectively, and the OR for this smoking
phenotype was 8.68 (2.47-30.46), p = 0.0005 for the A1-/9- genotype combination, relatively to the A1+/
9+. Carriers of *9 allele of SLC6A3 had over twice a lower risk to start smoking before the age of 20 years
compared to non-carriers (sex-adjusted OR = 0.44; 95% CI: 0.22-0.89; p = 0.0017), and subjects with A1-
/9- genotype combination had a higher risk for staring regular smoking before the age of 20 years in
comparison to subjects with A1+/9+ genotype combination (sex-adjusted OR = 3.79; 95% CI:1.03-13.90;
p = 0.003).
Conclusion: Polymorphic variants of DRD2 and SLC6A3 genes may influence some aspects of the smoking
behavior, including age of starting regular smoking, the level of cigarette consumption, and periods of
abstinence. Further large sample studies are needed to verify this hypothesis.
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Background
Tobacco smoking is a complex behaviour determined
both by genetic and environmental factors. Classical twin
studies demonstrated a strong heritability in the range of
40-70%, supporting a substantial genetic contribution to
tobacco use [1,2]. Allelic association studies conducted
from the beginning of the 1990s have indicated that pol-
ymorphisms in several candidate genes may predispose to
smoking initiation and nicotine dependence [3]. Recent
studies on tobacco smoking have focused on polymor-
phisms of genes involved in the neurotransmission of
dopamine in the central nervous system. The rationale for
such an approach ensues from the properties of nicotine
as the major addictive substance in tobacco smoke [4].
The pleasurable effects arising from nicotine are linked to
stimulation of the dopamine reward pathway after bind-
ing nicotine with receptors present on the dopaminergic
cell bodies, which in turn leads to an increased release of
dopamine in the nucleus accumbens of the mesolimbic sys-
tem [5,6].
A number of allelic association studies focused on poly-
morphism of gene for DRD2 dopamine receptor. Several
polymorphisms of this gene were identified, including
TaqIA polymorphisms [7]. Studies have shown that A1
allele is associated with a reduced dopamine D2 receptor
density [8-10]. It has been hypothesised that persons with
such a functional deficit in the dopamine reward pathway
experience an enhanced reward when exposed to
dopaminergic agents, including nicotine, thereby making
them more vulnerable to nicotine addiction [11]. Some
authors have demonstrated that cigarette smokers more
frequently carry A1  allele than never-smokers [11-13].
However, there is some inconsistency in the literature
regarding association of TaqI polymorphism of DRD2 and
smoking, with some studies indicating the lack of such an
association [14-16] and others reporting the association
of A2 allele with smoking [17]. More recently, common
TaqIA  polymorphism, originally thought to be in the
DRD2 gene, has been determined to be in a neighbouring
gene ANKK1 (ankyrin repeat and kinase domain controlling
1) [18]. However, being in linkage disequilibrium with
other variants in the DRD2 gene, but not with variants in
the ANKK1 gene, TaqIA polymorphism is considered to
have a strong association with DRD2 gene [19].
The dopamine transporter gene (SLC6A3) encodes a pro-
tein that regulates synaptic levels of dopamine in the
brain and has been studied as another candidate gene for
tobacco smoking [20-23]. A 40 base polymorphism of a
variable number of tandem repeats (VNTR) has been
described in the 3' untranslated region of this gene [24].
Initially, it was suggested that people who carry the less
frequent nine-repeat allele (*9R) of the dopamine trans-
porter gene are less likely to be smokers [20,23]. The 9-
repeat allele of SLC6A3 has also been associated with a
substantial reduction in dopamine transporter protein,
resulting in less clearance and greater bioavailability of
dopamine [25]. It was suggested that carriers of the com-
mon allele of SLC6A3, the 10-repeat allele, may achieve a
greater reward from nicotine's effect on dopamine activ-
ity. Thus the 9-repeat allele and eventually the higher level
of dopamine in the synaptic cleft appeared to play a pro-
tective role from smoking. However, it was subsequently
demonstrated that the 9-repeat allele enhances transcrip-
tion of the dopamine transporter protein, which might
result in a greater clearance of synaptic dopamine, and
thus lower basal availability [26,27]. In turn, some reports
suggest that there is no functional difference related to
particular polymorphism [28]. There are also some allelic
association studies which did not replicate the initial pos-
itive results [21,22].
In the light of existing discrepancies and of the lack of sur-
veys on the association between variant alleles of DRD2
and SLC6A3 genes and smoking in Poland, we investi-
gated whether polymorphic variants of these genes and
their combinations are associated with the smoking habit
in the Polish population.
Methods
The study sample and measures
Three hundred and ten adult subjects (150 ever-smokers
and 160 ethnically and gender matched never-smoking
controls), Caucasians, were recruited for study among
patients and staff of the Academic Clinical Centre in
Gdansk and outpatients of the Department of Family
Medicine, the Nicolaus Copernicus University of Torun,
Collegium Medicum in Bydgoszcz (NCUT-CMB). All sub-
jects were of Polish origin, inhabitants of the Pomeranian
region of Northern Poland. Smoking status was elicited
before recruitment to the study during face-to-face inter-
views. Ever-smokers were defined as individuals who have
smoked at least 100 cigarettes in their lifetime, and cur-
rent smokers were defined as individuals who, at the time
of the survey, smoked cigarettes either daily or occasion-
ally [29]. Never smoker was someone, who either had
never smoked at all or had never been daily smoker and
had smoked less than 100 cigarettes (or the equivalent
amount of tobacco) in his lifetime [29]. Former smokers
were defined as those who had quit smoking at least 1
year before the study. Written informed consent was
obtained from all subjects prior to participation in the
study, and all study procedures were approved by the
institutional research ethics committees at the Medical
University of Gdansk and the Nicolaus Copernicus Uni-
versity of Torun.
To verify recent non-smoking status, the measurement of
carbon oxide in exhaled air was performed in formerBMC Medical Genetics 2009, 10:92 http://www.biomedcentral.com/1471-2350/10/92
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smokers with the use of Micro CO smokelyser (Bedfont
Instruments, Kent, UK). Participants completed a short
questionnaire assessing sociodemographic data (age, gen-
der, educational level) and details on the subject's recent
and prior tobacco use (ever-/never-smoker status, number
of cigarettes smoked, age when regular smoking started,
number of years smoked). Current smokers were queried
about the longest period of abstaining from cigarettes in
the past, if any. All reported periods of maximal absti-
nence were further calculated into days. Pack-years were
calculated using the average number of cigarettes smoked
daily and the number of years smoked. Nicotine depend-
ence was scored with the use of the Fagerstrom Test for
Nicotine Dependence (FTND) [30].
From all subjects, 8 ml of venous blood samples were col-
lected into heparinised tubes. Samples were frozen and
stored at -80°C until required for molecular genotypic
analyses. Genomic DNA was extracted from lymphocytes
and used as a template for the PCR.
Genotyping
TaqI A sites of the DRD2 genotypes were determined by
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP), as previously described
[31,32]. The set of primers used was as described by Noble
et al. [33].
Allelic variants of SLC6A3  gene were characterised by
determining a 40-base-pair variable-number tandem
repeat in the 3' untranslated region on chromosome
5p16.3 according to Vanderberg et al. [24]. DNA amplifi-
cation by PCR of the 40 bp repeat was carried out as
described by Sano et al. [34]. The set of primers used was
as described by Vanderberg et al. [24].
Statistical analyses
The chi-squared (χ2) test was used to assess deviations of
genotype distribution from the Hardy-Weinberg equilib-
rium and for group comparisons of frequencies of allele
and genotype/genotype combinations. For analyses, we
grouped subjects as carriers and non-carriers, with carriers
defined as participants who tested positive for the pres-
ence of the allelic variants (A1/A1 + A1/A2 and 9/9+9/
10+9/11, versus A2/A2  and  10/10+10/11, respectively)
[7,20]. Univariate logistic regression analysis was per-
formed to search for variables potentially associated with
the increased risk for ever smoking, i.e. age and education
level (gender was not considered in this analysis because
of the gender-matching of the study sample), as well as
variables potentially increased with heavier smoking
(smoking ≥10 cigarettes daily) and earlier starting of reg-
ular smoking (before the age of 20 years), i.e. age, sex, and
education level. Multivariate logistic regression was per-
formed to examine whether given genotype/genotype
combinations were independently associated with an
increased risk of particular phenotypes. The association
between smoking status or smoking-related phenotypes
and genotype/genotype combinations was expressed by
ORs with 95% confidence bounds. Student's test t was
used to compare means for continuous variables (the U
Mann-Whitney test was used where data were not nor-
mally distributed). A significance level of 0.05 was set for
a type 1 error in all analyses, exluding those, in which
Bonferroni correction was needed.
Results
Out of 310 subjects, two unsuccessfully underwent geno-
typing, therefore they were excluded from the analyses.
Data for the remaining 308 subjects were analysed,
including 150 ever-smokers (67 females; mean age 53.1 ±
11.1) and 158 never-smokers (79 females; mean age 45.0
± 16.2). Distributions of genotypes for TaqIA polymor-
phism of DRD2 and SLC6A3 VNTR polymorphism did
not deviate to any appreciable extent from expectations
predicted by the Hardy-Weinberg equilibrium as deter-
mined by a chi-square test (p = 0.66 and p = 0.36, respec-
tively).
Allele frequencies for the DRD2 and the SLC6A3 genes
and genotypes in relation to smoking status are shown in
Table 1.
There were no differences in the distribution of DRD2 and
SLC6A3 genotypes or in the frequencies of *9 alleles of
SLC6A3 compared to pooled *10 and *11 alleles among
ever- and never-smokers. In turn, we found that frequency
of A1 alleles was lower in ever-smokers than in never-
smokers (p = 0.032). However, the OR for being an ever-
smoker for A1 allele carriers did not reach the assumed
level of statistical significance, when compared to A2
homozygous subjects and was 0.68 (95% CI: 0.42-1.09);
p = 0.108.
Similarly, distribution of genotype combinations did not
differ between ever- and never-smokers. Only 41.5% of
subjects with a genotype combination A1+/9- were ever-
smokers. A relative risk for this genotype combination for
ever-smoking as compared to subjects of all other geno-
type combinations pooled was 0.69 (95% CI: 0.40-1.21);
p = 0.192. In turn, the genotype combination A1-/9- was
the most strongly associated with ever-smoking status:
52.6% of carriers of this variant combination were ever-
smokers. However, OR for smoking for subjects of geno-
type combination A1-/9- compared to subjects of all other
genotype combinations pooled, as well as compared to
the genotype combination that had the lowest frequency
of smoking (A1+/9-), did not reach statistical significance
and were 1.28 (95% CI: 0.81-2.04), p = 0.288, and 1.56
(95% CI: 0.84-2.80), p = 0.152, respectively.BMC Medical Genetics 2009, 10:92 http://www.biomedcentral.com/1471-2350/10/92
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Comparison of mean values of smoking duration, age
when starting regular smoking, the number of cigarettes
smoked daily and the number of pack-years between ever-
smokers with DRD2*A1  or  SLC6A3*9, and those
homozygous for DRD2*A2 or SLC6A3*10 demonstrated
no differences. There were also no differences when FTND
scores for current smokers carrying A1 or *9 allele were
compared with those for non-carriers. Comparison of
mean length of the longest abstinence period on quitting
attempts between current smokers with DRD2*A1  or
SLC6A3*9 allele and non-carriers for these alleles demon-
strated that A1 allelic subjects were more likely to achieve
longer abstinence than non-carriers of A1 allele (314 ±
696 days v. 289 ± 925 days, p = 0.049), while no differ-
ence was observed between *9 allele carriers and non-car-
riers. In the smokers group quantitative measures of
smoking did not also relate to DRD2xSLC6A3 genotype
combinations.
Further, multiple analyses with the use of Bonferroni cor-
rection were performed to assess the association between
the  DRD2  and  SLC6A3  genotypes, as well as
DRD2xSLC6A3 genotype combinations and separate phe-
notypes of ever-smokers related to the number of ciga-
rettes consumed (subjects smoking up to 10 cigarettes/day
or occasionally vs heavier smokers), and the age at which
regular smoking had started (subjects who had started reg-
ular smoking before the age of 20 years versus subjects
starting regular smoking being twenty years old or older).
We found lower rates of A1 and *9 allele carriers in heav-
ier smokers than in light/occasional smokers (68% vs
85%; p = 0.02, and 71% vs 86%; p = 0.02, respectively).
Univariate logistic regression analysis demonstrated that
the risk of smoking more than 10 cigarettes daily did not
relate to age, sex or education level, while A1/A1+A1/A2
and 9/9 +9/10 genotypes appeared to decrease it (OR =
0.38 and OR = 0.39, respectively (Table 2). Furthermore,
a rate of *9 allele carriers among subjects who had started
regular smoking before the age of 20 years was lower than
among subjects who had started regular smoking later
(51% vs 32% p = 0.022). Univariate logistic regression
analysis showed that the risk of earlier transition of initial
smoking into regular habit was lower in women and *9
allele carriers (OR = 0.40; 95% CI: 0.21-0.80 and OR =
0.46; 95% CI: 0.23-0.90, respectively), and did not relate
to age and education level. Multivariate analysis, with sex
incorporated as a covariate, revealed that *9 allele carriers
had over twice a lower risk (sex-adjusted OR = 0.44; 95%
CI: 0.22-0.89) of starting smoking up to 20 year of life
than non-carriers. Stratification by sex revealed that this
association reached assumed significance level in males
(OR = 0.29; 95% CI: 0.11-0.74), but not in females (OR =
0.80; 95% CI: 0.27-2.35) (Table 2).
An estimation of the relationship between genotype com-
binations and particular smoking-related phenotypes
demonstrated that subjects with A1-/9-, A1-/9+ and A1+/
9- genotype combinations had nearly 8.7, 4.5, and 4.9
higher risk of being heavier smokers as compared to sub-
jects with A1+/9+ genotype combination (p = 0.0006, p =
0.014 and p = 0.02, respectively), and subjects with A1-/9-
genotype combination had nearly 4.0 higher risk to step
into regular smoking before the age of 20 years as com-
pared to A1+/9+ genotype status (sex-adjusted OR = 3.79;
95% CI: 1.03-13.90; p = 0.04). Stratification by sex indi-
cated possible association between A1-/9- genotype and
starting regular smoking before the age of 20 years in
males (OR = 7.64; 95% CI: 1.29-45.15) but not in females
(OR = 1.33; 95% CI: 0.20-8.70) (Table 3).
Table 1: DRD2 and SLC6A3 genotype distribution in ever smokers and never smokers from the North of Poland
Allele/Genotype Total No. of alleles/subjects % Ever-smokers % Never-smokers %
DRD2:
A1† 1 1 8 1 9 . 24 71 5 . 7 7 1 2 2 . 5
A2 498 80.8 253 84.3 245 77.5
A2/A2 204 66.2 106 70.7 98 62.0
A1/A2 90 29.2 41 27.3 49 31.0
A1/A1 14 4.5 3 2.0 11 7.0
SLC6A3
*9 1 3 8 2 2 . 46 72 2 . 3 7 1 2 2 . 5
*10 474 76.9 230 76.7 244 77.2
*11 4 0.6 3 1.0 1 0.3
10/10 1 7 8 5 7 . 88 65 7 . 3 9 2 5 8 . 2
9/10 1 1 5 3 7 . 35 63 7 . 3 5 9 3 7 . 3
9/9 11 3.6 5 3.3 6 3.8
11/10 3 1.0 2 1.3 1 0.6
11/9 1 0.3 1 0.7 0 0
† p = 0.032 in comparison of allele frequencies in ever- and never smokersBMC Medical Genetics 2009, 10:92 http://www.biomedcentral.com/1471-2350/10/92
Page 5 of 8
(page number not for citation purposes)
Discussion
Initial studies suggested that A1  alleles of dopamine
receptor D2 gene were associated with susceptibility to
smoking [11,12]. However, several studies failed to repli-
cate this association [14,15], while other studies on Japa-
nese populations indicated the link of A2  allele with
smoking behavior [17,35].
The results of our study demonstrated no association
between DRD2 genotypes and cigarette smoking. How-
ever, the frequency of A2 allele was significantly higher in
ever-smokers than in never-smokers. These findings might
suggest that A2 allele is more important as determinants
of smoking status, or that other factors, such as socioeco-
nomic, environmental or cultural ones, might contribute
relatively more than DRD2  genotypes in the smoking
habit among the Polish population.
In our retrospective analysis of quitting history in ever-
smokers we found that A1 allele carriers achieved longer
abstinence periods when they had attempted to quit than
non-carriers. However, this association was weak and one
could not rule out - false positive, considering the limited
sample size of the study and used threshold of p = 0.05.
Similarly, Spitz et al. [32] in the study conducted in the
sample of 283 subjects demonstrated that individuals
with A1 genotypes reported a slightly longer mean dura-
tion of smoking cessation than subjects with the A2 geno-
types. Other studies, however, yielded inconsistent results
Table 2: Odds ratios for DRD2 and SLC6A3 genotypes for separate phenotypes of smoking
Smoking phenotype ORs (95% CI)
DRD2 genotypes p-value SLC6A3 genotypes p-value
A1+ A1-* 9+* 9-
Ever smoking 0.68 (0.42-1.09) 1.47 (0.91-2.38) 0.108 1.00 (0.65-1.57) 0.99 (0.85-1.15) 0.972
Smoking >10 cig./day 0.38 (0.17-0.88) 2.63 (1.14-6.05) 0.0237* 0.39 (0.17-0.89) 2.59 (1.13-5.93) 0.0211*
Regular smoking before the age of 20 years 0.78† (0.37-1.64) 1.29† (0.61-2.69) 0.022* 0.44† (0.22-0.89) 2.27† (1.09-4.50) 0.00175*
Females 0.80 (0.27-2.35) 1.25 (0.43-3.67) 0.677**
Males 0.29 (0.11-0.74) 3.45 (1.36-8.79) 0.007**
† sex-adjusted ORs
* significance level after Bonferroni correction: p = 0.05/2 = 0.025
** significance level after Bonferroni correction: p = 0.05/3 = 0.017
Table 3: Numbers and frequencies of DRD2/SLC6A3 combinations, and odds ratios for these genotype combinations for separate 
smoking phenotypes
Genotype 
combinations
Light/Heavy smoking
No. (%)
OR (95% CI)
p-value
Early/late start of smoking
No. (%)
OR (95% CI)
p-value
≤10 cig./day >10 cig./day Before 20 year of 
life
In/after 20 year of 
life
A1+/9+ 9 (52.9) 8 (47.1) 1† 4 (23.5) 13 (76.5) 1†
A1+/9- 5 (18.5) 22 (81.5) 4.95 (1.22-20.08)
0.017*
13 (48.1) 14 (51.9) 3.02 (0.75-12.13)
0.096*
A1-/9+ 9 (20) 36 (80) 4.5 (1.32-15.32)
0.013*
16 (35.6) 29 (64.4) 1.79 (0.49-6.59)
0.357*
A1-/9- 7 (11.5) 54 (88.5) 8.68 (2.47-30.46)
0.0005*
32 (52.5) 29 (47.5) 3.79 (1.03-13.90)††
0.003*
Females 1.33 (0.20-8.70)
0.865**
Males 7.64 (1.29-45.15)
0.007**
†OR = 1 for genotype combination related to the lowest frequency of given smoking-related phenotype
††sex-adjusted OR
*significance level after Bonferroni correction: p = 0.05/2 = 0.025
**significance level after Bonferroni correction: p = 0.05/3 = 0.017BMC Medical Genetics 2009, 10:92 http://www.biomedcentral.com/1471-2350/10/92
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regarding a possible link of dopaminergic genes polymor-
phism with smoking cessation [36-38].
The present study also failed to replicate the association
between  SLC6A3  genotypes and smoking status. Simi-
larly, we found no difference in mean duration of the
longest abstinence achieved in the past between allele *9
carriers and non-carriers. Available data on the influence
of SLC6A3 gene and smoking cessation are also discord-
ant. Erblich et al. found that non-carriers of nine-repeat
allele could abstain from cigarettes for a longer period of
time than carriers [13]. In contrast, Lerman et al. reported
association between the absence of the nine-repeat allele
and shorter quit durations [20].
Reasons for non-replication of allelic association studies
in general were previously widely discussed [21,39]. It was
suggested, for instance, that more attention should be
focused on refining smoking behaviour phenotypes and
exploring genetic influences on them, rather than only on
smoking status per se [39]. In fact, only when separating
smokers according to their smoking phenotypes related to
the number of cigarettes smoked daily and age at starting
regular smoking, the possible association between studied
polymorphisms and heavier smoking or earlier entering
the phase of regular smoking was demonstrated in our
investigation. It is likely that other genes than DRD2 and
SLC6A3 have a greater impact on ever smoking status (i.e.,
smoking initiation), and simultaneously many other non-
genetic factors, including socio-demographical, pharma-
cological, psychological, behavioural or cultural ones,
independently influence vulnerability to smoking, while
these two dopaminergic genes might influence smoking
behaviour phenotypes. However, it is possible, that the
association between studied polymorphisms and these
smoking-related phenotypes was mediated by an
unknown confounder, for instance, linkage disequilib-
rium between a variant under study and true variant
related to given smoking-related phenotype. On the other
hand, it is likely that ethnical homogeneity of studied
population allowed to avoid confounding by ethnicity.
Our survey on association between genotypes and the
level of cigarette consumption demonstrated that the risk
for smoking a greater number of cigarettes daily was over
2.5 times lower in carriers than in non-carriers of A1 or *9
allele. Moreover, frequency of heavier smoking was the
lowest among subjects with A1+/9+ genotype combina-
tions. In turn, possessing even one common allele A2 or
*10 in DRD2xSLC6A3 combinations was associated with
a higher risk of heavier smoking, with A1-/9- genotypes
combination associated with the highest risk of heavier
smoking, relatively to the A1+/9+ genotype combination.
Previously, Spitz et al. [32] reported that A1 allele carriers
were less likely to smoke more cigarettes per day than
non-carriers. In turn, Yoshida et al. reported the lack of
apparent association between DRD2  genotype and the
number of cigarettes smoked daily [17]. Our study indi-
cated that also genotype combination DRD2/SLC6A3
might influence the level of cigarette consumption.
Namely, smokers with a relatively regular synaptic cleft
dopamine homeostasis might experience a greater reward
when stimulated by nicotine and, in consequence, they
might be apt to repeat this stimulation more frequently by
smoking cigarettes. Assuming the hypothesis that A1 car-
riers have a lower density of DRD2 receptors [8-10] and 9-
repeat allele carriers display decreased expression of
dopamine transporter [25], individuals with A1+/9+ gen-
otype combination might have a chronically high level of
extra-cellular dopamine protecting them from heavier
smoking. In fact, our findings that A1+/9+ genotype com-
bination had the lowest association with heavier smoking
might be explained by the higher dopamine availability
resulting from lower dopamine receptor density accompa-
nied by decreased activity of dopamine transporter, not
sufficient to uptake the whole amount of dopamine from
the synaptic cleft. Such subjects might have a lower need
to repeat dopaminergic stimuli, because of protracted
extracellular dopamine signalling.
Separating smokers by the age when they step onto the
stage of regular smoking revealed that carriers of *9 allele
of SLC6A3 were less likely to indurate the smoking habit
before the age of 20 years than non-carriers, and that this
association was modified by gender. In addition, with
combined DRD2 and SLC6A3 genotypes, subjects with
A1-/9- genotype combination had a higher risk for staring
regular smoking before the age of 20 years in comparison
to subjects with A1+/9+ genotype combination, with OR
reaching in males 7.6. Data from the initial study of Ler-
man et al. [20] on the association between SLC6A3 VNTR
polymorphism and smoking indicated that 9-repeat allele
carrier genotypes were significantly less likely to have
started smoking before 16 years of age. Our data are con-
sistent with the observation that polymorphism in the
SLC6A3 may play an important role in smoking onset and
progression to regular smoking, as well as indicate that
gender, independently influencing the age of induration
of smoking habit, might be a strong effect modifier.
As a limitations of the study the relatively small study
sample should be pointed out. It has resulted in quite
wide confidence intervals for subgroups referring to par-
ticular smoking phenotypes indicating uncertainty in the
result. Despite in several studied associations p-values
were smaller than used thresholds we are cautious in
interpreting arbitrary these findings as significant, keeping
in mind the possibility of false positivity due to chance
caused by random variation [40]. Thus, we present our
results as hypothesis-generating rather than confirmatoryBMC Medical Genetics 2009, 10:92 http://www.biomedcentral.com/1471-2350/10/92
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and consider that they need validation in studies con-
ducted on larger sample of smokers. However, although a
statistical power of the present study seems to be not ade-
quate, our study indicate an importance of extending the
allelic association studies by the investigation of the
potential link of candidate genes polymorphisms with
better defined smoking-related phenotypes rather than
only with smoking status per se.
Conclusion
Polymorphic variants of DRD2 and SLC6A3 genes might
influence some aspects of the smoking behavior, includ-
ing age of starting regular smoking, the level of cigarette
consumption, and periods of abstinence.
It might help in identifying special subgroups of smokers,
which, in turn, could have important clinical implications
for more successful interventions. It is likely, however,
that due to the great complexity of smoking behaviour,
which results from numerous genetic, environmental and
psychological influences, the knowledge of genetic risk
alone could be insufficient for the development of more
effectively targeted cessation therapy.
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